Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Increased by Factorial Partners LLC

Factorial Partners LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 332,000 shares of the company’s stock after buying an additional 21,000 shares during the quarter. Teva Pharmaceutical Industries makes up about 4.2% of Factorial Partners LLC’s holdings, making the stock its largest position. Factorial Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $7,317,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Creative Planning lifted its stake in Teva Pharmaceutical Industries by 4.5% in the 3rd quarter. Creative Planning now owns 42,815 shares of the company’s stock valued at $772,000 after buying an additional 1,863 shares in the last quarter. Private Advisor Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Private Advisor Group LLC now owns 26,104 shares of the company’s stock valued at $470,000 after acquiring an additional 2,990 shares in the last quarter. Diversify Advisory Services LLC lifted its position in shares of Teva Pharmaceutical Industries by 95.3% in the third quarter. Diversify Advisory Services LLC now owns 19,859 shares of the company’s stock valued at $365,000 after acquiring an additional 9,693 shares in the last quarter. Diversify Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at $640,000. Finally, Gladstone Institutional Advisory LLC increased its position in Teva Pharmaceutical Industries by 847.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 143,939 shares of the company’s stock worth $2,594,000 after purchasing an additional 128,748 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.45 on Friday. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a market cap of $18.64 billion, a PE ratio of -11.34, a P/E/G ratio of 1.44 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company’s fifty day simple moving average is $19.65 and its 200-day simple moving average is $18.46.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.57.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.